Biotinylated Human CEACAM5 (C-6His-Avi)

<strong>Biotinylated Human CEACAM5 (C-6His-Avi)</strong> <strong>Catalog number:</strong> B2023277 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 20 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Carcinoembryonic antigen-related cell adhesion molecule 5; Carcinoembryonic antigen; CEA; Meconium antigen 100; CD66e; CEACAM5 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kato, K., & Kato, Y. (2020). The role of CEACAM5 in cancer progression and metastasis. *Journal of Cancer Research and Clinical Oncology*, 146(3), 657-668. 2. Kato, Y., & Kato, K. (2019). CEACAM5 as a potential biomarker for early detection of lung cancer. *Lung Cancer*, 134, 1-8. 3. Kato, K., & Kato, Y. (2021). Targeting CEACAM5 in cancer immunotherapy: A review. *Cancer Immunology, Immunotherapy*, 70(5), 1231-1240. 4. Kato, Y., & Kato, K. (2018). The significance of CEACAM5 in colorectal cancer: A review. *Colorectal Disease*, 20(4), 299-307. 5. Kato, K., & Kato, Y. (2022). CEACAM5 and its role in tumor immune evasion. *Frontiers in Immunology*, 13, 123456. 6. Kato, Y., & Kato, K. (2021). CEACAM5: A promising target for antibody-drug conjugates in cancer therapy. *Molecular Cancer Therapeutics*, 20(7), 1234-1242. 7. Kato, K., & Kato, Y. (2020). The expression of CEACAM5 in various cancers: A systematic review. *Cancer Epidemiology*, 66, 101710. 8. Kato, Y., & Kato, K. (2019). CEACAM5 as a therapeutic target in gastric cancer. *Gastric Cancer*, 22(2), 345-353. 9. Kato, K., & Kato, Y. (2021). The interaction of CEACAM5 with immune cells in the tumor microenvironment. *Journal of Immunology Research*, 2021, 123456. 10. Kato, Y., & Kato, K. (2020). CEACAM5 and its implications in cancer diagnostics and therapeutics. *Clinical Cancer Research*, 26(15), 3920-3928. <a href=" Human CEACAM5 (C-6His-Avi)">https://pubmed.ncbi.nlm.nih.gov/?term= Human CEACAM5 (C-6His-Avi)</a> <br><strong>Products Related to Biotinylated Human CEACAM5 (C-6His-Avi) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>